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Abstract
Pancreatic cancer ranks fifth as a cause of cancer-related death in the world with an overall 5-year
survival rate of less than 1% and a median survival of less than a year after tumour detection. Most
of these patients have already metastases at the time of diagnosis. The oncologic strategies such as
chemotherapy, radiotherapy, antihormonal modalities or the systemic use of specific monoclonal
antibodies have not achieved a significant improvement in the survival of pancreatic cancer patients.
Recent studies suggest that alterations in molecular pathways, particularly in growth factor
mediated mechanisms, that regulate cell proliferation and differentiation play a pivotal role in the
pathogenesis of this cancer. The molecular knowledge regarding changes in the expression of
growth factors in pancreatic cancer has the potential to improve diagnostic and therapeutic
treatment strategies in the near future.
Introduction
Pancreatic cancer most frequently affects men between 60
and 80 years of age. This disease ranks fifth as a cause of
cancer-related death in the world with an overall 5-year
survival rate of less than 1% and a median survival of ap-
proximately 5–6 months after tumour detection [1]. The
currently available diagnostic tools usually do not detect
early stages of cancer and as a consequence, most of these
patients have already metastases at the time of their first
visit. Recent studies suggest that alterations in the molec-
ular pathways that regulate cell proliferation and differen-
tiation play a pivotal role in the pathogenesis of this
cancer. These changes result in abnormalities in growth
factor mediated signaling cascades and cell cycle control.
Since the oncologic strategies such as chemotherapy, radi-
otherapy, antihormonal modalities or the systemic use of
monoclonal antibodies have not achieved a significant
improvement in the survival of pancreatic cancer patients,
great efforts have been undertaken in investigating new
treatment approaches that, based on the specific molecu-
lar changes of growth factor expression, could lead to nov-
el treatment concepts in the management of pancreatic
cancer.
Pathogenesis of pancreatic cancer
The pathogenesis of pancreatic cancer is nowadays de-
scribed as a model of step-by-step accumulation of genetic
and molecular changes leading to defects in cell growth,
cell adhesion and integration of epithelial cells. The alter-
ations in pancreatic cancer include changes in the expres-
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sion of oncogenes, inactivation of tumour suppressor
genes and aberrant expression of cyclins (proteins regulat-
ing cell cycle).
The K-ras oncogene seems to play the most important role
in the pathogenesis of pancreatic cancer, since it is mutat-
ed in 90% of pancreatic cancer cases [2–4]. K-ras is a gua-
nyl-nucleotide binding protein with GTPase activity that
mediates intracellular signaltransduction of growth fac-
tors that bind to tyrosine-kinase receptors. The most com-
mon mutations are localized at codons 12, 13 or 61 and
render the protein unable to hydrolyze GTP and thereby
continually transduce unregulated proliferative signals.
Further studies on experimental models of pancreatic can-
cer and chronic pancreatitis revealed that this mutation
appears in the early phase of malignant transformation of
ductal epithelial cells [5]. However, the value of the K-ras
oncogene as an indicator of malignant transformation of
the exocrine pancreas and the possible application of K-
ras as a molecular-diagnostic test are biased by the fact
that K-ras mutations can be detected in hyperplastic and
metaplastic lesions in tissues from normal pancreas or
chronic pancreatitis as well [5,6].
The p53 tumour suppressor gene is the most commonly
mutated gene in the carcinogenesis of epithelial cancers:
mutations of this gene are present in 40% of pancreatic
cancer [7–9]. Point mutations of p53 lead to the accumu-
lation of p53 proteins in the nucleus. However, p53 can
be inactivated through MDM2, the expression of this gene
is also increased in pancreatic cancer [10]. The most im-
portant functions of p53 are the regulation of the cell cy-
cle, e.g. the G1/S transition, and the induction of
apoptosis. The activation and progression of the cell cycle
is regulated by the activity of cyclins and cyclin-dependent
kinases (CDK). WAF1, that is activated by wild type p53,
but not by mutated p53, inhibits the activation of cyclin-
CDK complex and the phosphorylation and inactivation
of Retinoblastoma proteins thereby stopping the progres-
sion of cell cycle in phase G1. Cyclin D1 is also overex-
pressed in pancreatic cancer and this overexpression is
associated with a worse prognosis. In a study comparing
pancreatic cancer to chronic pancreatitis, mutations of the
p53 gene were detected in 47% of pancreatic cancers, but
not in any of the chronic pancreatitis cases [9].
Inactivation of the APC gene is found in approx. 30% of
gastric and colorectal cancer. In pancreatic cancer, a Japa-
nese group detected APC mutations in up to 40% of cases
but this result could not be confirmed by others [6]. On
the contrary, loss of heterozygosity (LOH) of the DCC
gene was reported in approx. 60% of pancreatic cancers
[11]. Moreover, Hahn et al found LOH at chromosome
18q as well. Further studies of this group led to the iden-
tification of the DPC4 gene that is inactivated in approx.
50% of pancreatic cancer [12]. DPC4 belongs to the group
of Smad-genes that mediate the signaltransduction of the
TGF-β family. Inactivation of Smad-proteins can result in
loss of the growth-inhibitory effects of TGF-β1 which
plays a central role in the pathogenesis of pancreatic can-
cer. Thus, pancreatic cancer cell growth, despite TGF-β1
overexpression, may be supported by defects in DPC4 or
the TGF-β-recptor II. Furthermore, the loss of Smad4/
DPC4-expression along with the inhibition of Smad2/3-
expression through the ras-protein can lead to the resist-
ance of epithelial cells against the growth-inhibitory and
antiproliferative function of TGF-β1 [13]. Interestingly,
Smad4/DPC4 also leads to the induction of p21/WAF1 so
that Smad4 can contribute to the inhibition of cell cycle
via the activation of WAF1 [14].
The inactivation of the p16 gene on chromosome 9p21 is
another essential genetic alteration in pancreatic cancer
[15]. This gene encodes the p16-inhibitor of the Cyclin D/
CDK-4 complex thereby regulating the coordinated pro-
gression of cell cycle [16]. Inactivation of p16 or other
genes involved in this signalling pathway can be detected
in approx. 90% of pancreatic cancer cases [17]. Mutations
of the p16 gene are reported in approx. 40% of cases, de-
letions in approx. 40% of cases, and loss of transcription
due to hypermethylation of the promoter region is re-
sponsible for the rest of the cases [14].
Impaired function of DNA repair genes leading to the de-
velopment of microsatellite instability have been de-
scribed in colorectal and gastric cancers. Replication error
positive cases are found in approx. 30–40% of gastric and
colorectal cancer whereas this mechanism seems to play
only a minor role in pancreatic cancer [18]. However, Han
et al found the same type of replication error in 6 out of 9
ductal pancreatic cancer cases [19].
Growth factors and pancreatic cancer
Growth factors are produced by many different cell types
and exert their effects via autocrine and paracrine mecha-
nisms. They function as stimulators or inhibitors of the di-
vision, differentiation and migration of cells and are
involved in carcinogenesis, in which they influence a vari-
ety of functions including cell proliferation, cell invasion,
metastasis formation, angiogenesis, local immune system
functions and extracellular matrix synthesis. The molecu-
lar knowledge acquired regarding changes in the expres-
sion of growth factors in pancreatic cancer has the
potential to improve diagnostic and therapeutic treatment
strategies in the near future [20].
Epidermal Growth Factor Family
In pancreatic cancer, coexpression of the epidermal
growth factor (EGF) receptor and EGF and/or transform-
ing growth factor (TGF)-α or amphiregulin results in aMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/5
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worse survival. Furthermore, the upregulation of EGF and
the EGF receptor is even more frequent in pancreatic ade-
nocarcinoma with lymph node and distant metastases
[21,22]. A marked increase in the expression of human
EGF receptor has proven to be associated with advanced
tumour stage and significantly shorter survival [23]. EGF,
TGF-α, HB-EGF and amphiregulin significantly enhance
the proliferation of human pancreatic cancer cell lines
[22]. Dysplastic changes were found in 50% of the TGF-α
transgenic mice, and pancreatic cancers were reported in
approximately 20% of TGF-α transgenic mice older than
1 year [24].
Fibroblast Growth Factor Family
Fibroblast growth factor (FGF) receptors are expressed by
human pancreatic cancer cell lines as well [25]. Glypican-
1 seems to be the most important coreceptor for heparin-
binding growth factors being overexpressed in a large pro-
portion of pancreatic cancers. The glypican-1 expression
occurs predominantly in the cancer cells and in the fibrob-
lasts surrounding the tumour mass. Reduction in glypi-
can-1 expression results in the attenuation of the
responsiveness of pancreatic cancer cells to heparin-bind-
ing growth factors [27]. In addition, transfection of a trun-
cated FGFR-1 into PANC-1 cells induces the blockade of
FGF receptor-dependent pathways and reduces tumour
growth in nude mice [28]. FGFs and their receptors are
suggested to play a critical role in tumour angiogenesis in
a transgenic mouse model of pancreatic β-cell carcinogen-
esis as well [29].
Transforming Growth Factor-β
Cancer cells are resistant to the growth-suppressive effects
of transforming growth factor(TGF)-β [30]. The overex-
pression of TGF-β isoforms is associated with a poor prog-
nosis in pancreatic cancer [31]. The inactivation of Smad4
which is part of the TGF-β signalling pathway is common
(up to 42%) in this cancer [32]. According to in situ hy-
bridization analyses, Smad6 and Smad7 (TGF-β signaling
inhibitors) are also overexpressed in the cancer cells with-
in the tumour mass. Following transfections with Smad6
and Smad7, a complete blockade of the growth-inhibitory
effects of TGF-β occurred in the TGF-β-responsive pancre-
atic cancer cell line COLO-357 and in nude mice [33,34].
Thus, pancreatic cancer cells might have multiple mecha-
nisms to avoid the suppressive effect of TGF-β and thereby
can retain the capability to express metastasis-promoting
genes.
Vascular Endothelial Growth Factor
Vascular endothelial growth factor (VEGF) plays an im-
portant role in tumour angiogenesis. Its two shorter iso-
forms (VEGF121 and VEGF165) induce angiogenic effects
by binding to the specific transmembrane tyrosine kinase
receptors KDR/flk-1 and flt-1, respectively, which are ex-
pressed selectively on endothelial cells. A significant cor-
relation was observed between VEGF positivity and
microvascular density (MVD) [35]. Moreover, VEGF ex-
pression was found to be associated with K-ras mutation
[36]. Several groups demonstrated that patients with pan-
creatic cancer showing moderate or high VEGF expression
have significantly shorter survival than patients with low
or without any VEGF expression [35–38]. Luo et al, re-
ported that stable transfection of an anti-sense VEGF(189)
into PANC-1 pancreatic cancer cells resulted in decreased
VEGF expression and secretion, a decreased capacity of the
resultant conditioned medium to enhance endothelial
cell proliferation and a significant attenuation of tumour
cell proliferation in vitro, and when injected into athymic
nude mice, the antisense-VEGF(189)-expressing cells ex-
hibited an 80% decrease in tumour growth compared to
control cells [39].
Platelet-Derived Growth Factor Family
Platelet derived growth factors (PDGF) are proteins con-
sisting of A and/or B chains [40]. Through disulphide
bonds they can form the three isoforms PDGF-AA, -AB-, -
BB [41]. Two PDGF receptors have been cloned and char-
acterized, all of which possess tyrosine-kinase activity.
PDGFs have several biological functions, including their
mitogenic and chemoattractant role towards fibroblasts,
monocytes and endothelial cells. Furthermore, they play
an important role in wound healing and repair [42,43].
With regard to the formation of tumors, they have been
shown to stimulate the production of stromal tissue in
malignant tumors, thereby potentially contributing to the
development and progression of human cancers [44,45].
The expression of PDGFs is induced by TGF-β1 in pancre-
atic cancer cells and both PDGF receptors are overex-
pressed in this malignancy.
Nerve Growth Factor
The tumourous infiltration of pancreatic nerves is a well-
known phenomenon causing severe pain in the back
which is often the first clinical manifestation of pancreatic
cancer. The involvement of the extrapancreatic nerve plex-
us leads to retropancreatic tumour extension, inhibits cur-
ative resection, enhances local recurrence and reduces the
prognosis of pancreatic cancer patients [46]. The expres-
sion of nerve growth factor (NGF) and TrkA (the high-af-
finity receptor for NGF) is significantly higher in
pancreatic cancer than in normal pancreas, and this over-
expression is associated with more frequent perineural in-
vasion and a higher degree of pain [47,48].
Future perspectives in the treatment of pancre-
atic cancer
Pancreatic cancer obtains a significant growth advantage
through autocrine and paracrine mechanisms of several
growth factors, therefore novel therapeutic modalities areMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/5
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designed focusing on abrogating signaling of these lig-
ands. Hereby we summarize the most promising thera-
peutic approaches executed on human cancer cell lines or
in animal models of pancreatic cancer.
Epidermal Growth Factor
Nude mice were treated with a novel orally given EGF-R
tyrosine kinase inhibitor, PKI 166 (4-(R)-phenethylami-
no-6-(hydroxyl)phenyl-7H-pyrrolo [2.3-d]-pyrimidine),
7 days after orthotopic injection of L3.6pl human pancre-
atic cancer cells. The volume of pancreatic cancers was re-
duced by 59% in mice treated with gemcitabine, by 45%
in mice treated with PKI 166, and by 85% in those treated
with both drugs. The combination therapy also signifi-
cantly inhibited lymph node and liver metastasis forma-
tion, which led to a significant improvement in overall
survival. EGF-R activation was significantly blocked by
therapy with PKI 166 and was associated with a significant
decrease in tumour cell production of VEGF and IL-8,
which correlated with a significant reduction in angiogen-
esis, and an increase in apoptotic tumour and endothelial
cells [49–51].
By blocking the conversion of 3-Hydroxy-3-methylglutar-
yl-coenzyme A (HMG-CoA) to mevalonate, HMG-CoA re-
ductase inhibitors (i.e. fluvastatin and lovstatin) inhibit
the synthesis of other products derived from this metabo-
lite. EGF induced a dose-dependent increase of PANC-1
cell invasion in vitro. Treatment of PANC-1 cells with flu-
vastatin markedly attenuated EGF-induced translocation
of RhoA from the cytosol to the membrane fraction and
actin stress fiber assembly, whereas it did not inhibit the
tyrosine phosphorylation of EGF receptor and c-erbB-2
[52].
Vascular Endothelial Growth Factor
In pancreatic cancer, VEGF expression and the degree of
MVD, which are closely correlated, are reliable markers of
early tumour recurrence after resection. The soluble form
of flt-1 VEGF receptor inhibits VEGF activity. PANC-1 and
PK-8 were utilized as lower- and higher-VEGF-producing
cell lines, respectively. The in vitro proliferation of cancer
cells infected with adenovirus vectors encoding soluble
flt-1 (Adsflt) and control vectors (AdLacZ) exhibited no
difference. Cancer cells were inoculated in severe com-
bined immunodeficient (SCID) mice in order to evaluate
the in vivo tumour growth suppression. Adsflt, AdLacZ, or
vehicle was injected directly into the tumours. The tumour
growth and the MVD of the Adsflt-treated group was sig-
nificantly inhibited both in PANC-1 cells and PK-8 cells.
Apoptosis index increased and tumour angiogenesis de-
creased in the Adsflt group in contrast to groups of wild-
type cells and AdLacZ-infected cells [53,54].
Injection of 100 mg/kg of SU6668 (inhibitor of the recep-
tor-tyrosine kinase activity of VEGF, FGF, and PDGF)
markedly suppressed tumour growth and decreased tu-
mour blood flow in CFPAC human pancreatic carcinoma
cells and additionally extended survival in tumour-bear-
ing mice compared to control. Daily SU6668 administra-
tion and a single dose of 15 Gy of X-irradiation was
significantly more effective than either treatment alone in
suppressing tumour growth [55].
Platelet-Derived Growth Factor
The recent introducton of the signal transduction inhibi-
tor imatinib mesylate (formerly ST1571) has had an im-
portant influence on the practice of oncology as well as on
the process of drug development [56]. Imatinib mesylate
was originally designed to specifically target chronic mye-
loid leukemia (CML) by blocking bcr-abl oncoprotein
[57]. Having obtained larger amount of experience, imat-
inib mesylate proved to have a striking activity against gas-
trointestinal stromal tumours (GISTs) as well by blocking
c-kit [58]. PDGF was one of the first polypeptide growth
factors identified that signals through a cell surface tyro-
sine kinase receptor to stimulate several cellular functions
including growth, proliferation, and differentiation in
various cancers such as prostate and pancreatic cancer
[59]. Since imatinib mesylate inhibits the PDGF-R kinase
Table 1: Summary of experimental modulation of growth factors in the treatment of pancreatic cancer
Target molecule Applied agent Effects Cancer cells / mouse modells Reference
EGF-R PKI 166 (+gemcitabine) inhibition of lymph node and liver 
metastases and angiogenesis
L3.6pl 44
VEGF-R adenovirus vectors encoding 
soluble flt-1
suppression of tumour growth, 
angiogenesis and MVD, increase 
of apoptosis
PANC-1 and PK-8 48
EGF-R, VEGF-R, PDGF-R SU6668 (+irradiation) suppression of tumour growth 
and tumour blood flow
A/J mice, C3H mice, Balb/
cAnNCrl-nuBr nude mice
50
HGF NK4 inhibition of tumour growth, 
peritoneal dissemination, ascites 
accumulation
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activity, it could possibly be a potent therapeutical ap-
proach for pancreatic cancer as well.
Hepatocyte Growth Factor
Hepatocyte growth factor (HGF) enhances tumour inva-
sion and metastasis through tumour-stromal interactions.
NK4 is a four-kringle fragment of HGF and acts as an
HGF-antagonist and an angiogenesis inhibitor. NK4
blocked the conversion of orthotopic pancreatic tumours
from in situ carcinoma to invading cancers during days 3–
14, when administration of NK4 was started from the
third day after orthotopic injection of SUIT-2 human pan-
creatic cancer cells into nude mice. NK4 therapy, started
on day 10 when cancer cells were already invading sur-
rounding tissues, suppressed tumour growth, peritoneal
dissemination, and ascites accumulation resulting in the
improvement of survival rates. The antitumour effects of
NK4 correlated with the reduction of MVD [60].
Conclusion
Molecular alterations in cellular pathways that regulate
normal cell growth and differentiation are associated with
the development of pancreatic cancer. Recently developed
assays for the detection of such genetic markers might be-
come useful diagnostic tools. The pharmacological ma-
nipulation of growth-factor mediated signaling cascades
and the molecular inactivation of growth regulatory path-
ways using specifically designed tyrosine kinase inhibitors
or other gene targeting techniques are beginning to be ap-
plied in the treatment of this cancer. This should lead to
improvements in diagnostic and therapeutic strategies
and subsequently result in a better prognosis of patients
with pancreatic cancer.
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